Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: treat-to-target

Study Finds Health & Financial Benefits in AxSpA Treat-To-Target Strategy

Thomas R. Collins  |  September 11, 2020

EULAR 2020 e-CONGRESS—In what speakers at the European e-Congress of Rheumatology described as the first treat-to-target and tight control (T2T/TC) strategy trial in axial spondyloarthritis (AxSpA), researchers found such a strategy has both health and financial benefits. In the year-long study—called TICOSPA—centers were randomized to apply either a T2T/TC strategy or care left to the…

Filed under:Axial SpondyloarthritisConditions Tagged with:axial spondyloarthritis (SpA)Disease Activity Score (DAS)EULARTreat-to-Target

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks  |  March 16, 2020

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Rheumatoid Arthritis (RA)Treat-to-Target

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

Filed under:ConditionsRheumatoid Arthritis Tagged with:imagingMagnetic resonance imaging (MRI)MRIRheumatoid Arthritis (RA)Treat-to-TargetUltrasound

More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations

Gretchen Henkel  |  April 17, 2019

A post-hoc analysis of data from two large clinical trials supports treat-to-target recommendations for patients with rheumatoid arthritis. The research found baseline disease activity was the strongest predictor of a patient’s insufficient response to initial therapy at six months…

Filed under:ConditionsRheumatoid Arthritis Tagged with:biologic therapiesrecommendationsRheumatoid Arthritis (RA)Treat-to-Target

Ultrasound as RA Treat-to-Target Strategy Doesn’t Improve Long-Term Outcomes

Larry Beresford  |  December 18, 2018

An analysis of treat-to-target therapy assessing two ultrasound definitions of remission for patients with early rheumatoid arthritis (RA) has concluded that using ultrasound remission as a target was not associated with better long-term outcomes for RA patients.1 Compared with MRI, ultrasound costs less, is more accessible and offers the ability to scan more joints in…

Filed under:Research RheumRheumatoid Arthritis Tagged with:Remission CriteriaUltrasound

SLE Remission: The Treat-to-Target Approach

Susan Bernstein  |  March 17, 2018

SAN DIEGO—Treatment strategies for systemic lupus erythematosus (SLE) have changed a great deal over the years, but progress has been slow and inadequate. According to a 2011 survey, many patients with lupus still report that they have a low quality of life due to their health problems.1 Rheumatologists face the challenge to develop more successful…

Filed under:Meeting ReportsSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingLupusRemissionSLE

Treat-to-Target Strategy Evaluated for Fibromyalgia Care

Susan Bernstein  |  September 19, 2017

Treat-to-target is a widely used approach for rheumatoid arthritis, in which rheumatologists prescribe treatments to reach established benchmarks of disease activity.1 Is it time for a similar approach for fibro­myalgia treatment, even though its pathogenesis, disease-activity measures and treatment algorithms are less well understood? Three fibromyalgia researchers present their case in a new paper, “Treat-to-Target…

Filed under:ConditionsPain SyndromesResearch RheumSoft Tissue Pain Tagged with:ACR Journal ReviewAmerican College of Rheumatology (ACR)criteriaFibromyalgiaPainResearchrheumatologyStrategyTreatment

2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA

Michele B. Kaufman, PharmD, BCGP  |  August 7, 2017

An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…

Filed under:Axial SpondyloarthritisConditions Tagged with:axial spondyloarthritis (SpA)Guidelinesperipheral spondyloarthritisrecommendationstarget

Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs

Michele B. Kaufman, PharmD, BCGP  |  July 6, 2016

In a recent study, 100% of patients with rheumatoid arthritis (RA) on infliximab experienced a cross-reaction when switched to its biosimilar (CT-P13, infliximab-dyyb). Plus in a recent study, a treat-to-target strategy proved effective for treating RA with biological disease-modifying anti-rheumatic drugs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiologicsBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)infliximabinfliximab-dyybRheumatoid Arthritis (RA)

Better Evidence Supports Slightly Revised Treat-to-Target Recommendations for RA

Will Boggs, MD  |  June 1, 2015

NEW YORK (Reuters Health)—A number of recent studies support last year’s update of 2010 treat-to-target recommendations for rheumatoid arthritis (RA), according to the international task force that revised them. Dr. Josef S. Smolen from Medical University of Vienna, Austria, and colleagues updated their 2010 advice based on systematic literature reviews and expert opinion. They left…

Filed under:ConditionsRheumatoid Arthritis Tagged with:recommendationRemissionRheumatiod arthritis

  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences